beta

AKRX

Akorn Inc.

Akrx

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-06-2018 08-01-2018 03-01-2017 11-03-2016 08-04-2016 05-16-2016 after market close
Actual EPS -0.1 -0.06 0.56 0.53 0.56 0.53
Consensus EPS 0.07 0.08 0.55 0.52 0.53 0.53
Estimated EPS 0.07 0.08 0.55 0.52 0.53 0.53
Number of Estimates 3 2 7 7 7 3
EPS Surprise -$0.17 -$0.14 $0.01 $0.01 $0.03

Stats

Summary

Akorn Inc is a United States based generic pharmaceutical company. It develops, manufactures and markets generic and branded prescription pharmaceuticals as well as private-label over-the-counter consumer health products and animal health pharmaceuticals.

Market Cap: 4.08 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.akorn.com

Shares Outstanding: 125 Million

Float: 119 Million

Dividend: 0.0 (0.0%)

Beta: 1.315309

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 25.7 Million

Ethical Flags

Animal testing

Longest drawdown: 916 trading days

From: 2015-04-23 To: 2018-12-14

Lowest Point:

Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)

via: Business Wire at 2018-12-10 15:18:00:000

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (NasdaqGS: AKRX) has filed a shareholder lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharma… read more...

Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)

via: Business Wire at 2018-12-10 15:18:00:000

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (NasdaqGS: AKRX) has filed a shareholder lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharma… read more...

Generics under pressure on expanded price-fixing investigation

via: SeekingAlpha at 2018-12-10 12:53:46:000

The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...

Generics under pressure on expanded price-fixing investigation

via: SeekingAlpha at 2018-12-10 12:53:46:000

The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...

Microcaps tops midday movers

via: SeekingAlpha at 2018-12-07 12:48:19:000

Gainers: Tenax Therapeutics (NASDAQ: TENX ) +129% . Sears Hometown and Outlet Stores (NASDAQ: SHOS ) +22% . Cronos Group (NASDAQ: CRON ) +22% . NF Energy Saving (NASDAQ: NFEC ) +20% . Domo (NASDAQ: DOMO ) +20% . VIVUS (NASDAQ: VVUS ) +19% . Comtech Telecommunications (NASDAQ: C… read more...

Microcaps tops midday movers

via: SeekingAlpha at 2018-12-07 12:48:19:000

Gainers: Tenax Therapeutics (NASDAQ: TENX ) +129% . Sears Hometown and Outlet Stores (NASDAQ: SHOS ) +22% . Cronos Group (NASDAQ: CRON ) +22% . NF Energy Saving (NASDAQ: NFEC ) +20% . Domo (NASDAQ: DOMO ) +20% . VIVUS (NASDAQ: VVUS ) +19% . Comtech Telecommunications (NASDAQ: C… read more...

Microcaps tops midday movers

via: SeekingAlpha at 2018-12-07 12:48:19:000

Gainers: Tenax Therapeutics (NASDAQ: TENX ) +129% . Sears Hometown and Outlet Stores (NASDAQ: SHOS ) +22% . Cronos Group (NASDAQ: CRON ) +22% . NF Energy Saving (NASDAQ: NFEC ) +20% . Domo (NASDAQ: DOMO ) +20% . VIVUS (NASDAQ: VVUS ) +19% . Comtech Telecommunications (NASDAQ: C… read more...

CNAT, MDXG, AKRX and TROX among midday movers

via: SeekingAlpha at 2018-12-06 12:43:49:000

Gainers: Uxin (NASDAQ: UXIN ) +31% .TheStreet (NASDAQ: TST ) +31% . KLX Energy Services Holdings (NASDAQ: KLXE ) +28% . Remark Holdings (NASDAQ: MARK ) +23% . CorMedix (NYSEMKT: CRMD ) +17% . Safe-T Group (NASDAQ: SFET ) +16% . NF Energy Saving (NASDAQ: NFEC ) +16% . Aqu… read more...

Akorn down 7% premarket on slim chances of reviving Fresenius deal

via: SeekingAlpha at 2018-12-06 09:09:38:000

Akorn (NASDAQ: AKRX ) slips 7% premarket on light volume in apparent reaction to the low probability that it will successful in its appeal of a court decision allowing former suitor Fresenius SE ( OTCQX:FSNUF ) to back out of its $4.75B takeover. More news on: Akorn, Inc., Fres… read more...

Tracking John Paulson's Paulson & Company Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-20 07:19:53:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulsons 13F stock portfolio on a quarterly basis. It is based on Paulsons regulatory 13F Form filed on 11/14/2018. Please visit our Tracking John Paulsons Paulson & Co… read more...

Tracking John Paulson's Paulson & Company Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-20 07:19:53:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulsons 13F stock portfolio on a quarterly basis. It is based on Paulsons regulatory 13F Form filed on 11/14/2018. Please visit our Tracking John Paulsons Paulson & Co… read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Express Scripts launches new formulary aimed at reducing drug costs

via: SeekingAlpha at 2018-11-13 09:43:56:000

Express Scripts (NASDAQ: ESRX ) introduces its National Preferred Flex Formulary covering more than 3,800 branded and generic medicines. More news on: Express Scripts, Inc., Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks news, Read more … read more...

Akorn, Inc: Business Is In Distress

via: SeekingAlpha at 2018-11-07 15:50:49:000

Akorn, Inc. ( AKRX ) develops, manufactures, and markets prescription and generic drugs. The prescription business makes up about 90% of revenues. AKRX's stock price hints about the drama the company has been embroiled in, as the firm agreed to be acquired by German pharmaceutical company Fr… read more...

Akorn, Inc: Business Is In Distress

via: SeekingAlpha at 2018-11-07 15:50:49:000

Akorn, Inc. ( AKRX ) develops, manufactures, and markets prescription and generic drugs. The prescription business makes up about 90% of revenues. AKRX's stock price hints about the drama the company has been embroiled in, as the firm agreed to be acquired by German pharmaceutical company Fr… read more...

Akorn, Inc: Business Is In Distress

via: SeekingAlpha at 2018-11-07 15:50:49:000

Akorn, Inc. ( AKRX ) develops, manufactures, and markets prescription and generic drugs. The prescription business makes up about 90% of revenues. AKRX's stock price hints about the drama the company has been embroiled in, as the firm agreed to be acquired by German pharmaceutical company Fr… read more...

Tech and consumer goods stock down in premarket trade

via: SeekingAlpha at 2018-11-07 09:22:06:000

The TJX Companies (NYSE: TJX ) -49% . More news on: TJX Companies Inc., MiMedx Group Inc., Infinera Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Tech and consumer goods stock down in premarket trade

via: SeekingAlpha at 2018-11-07 09:22:06:000

The TJX Companies (NYSE: TJX ) -49% . More news on: TJX Companies Inc., MiMedx Group Inc., Infinera Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Tech and consumer goods stock down in premarket trade

via: SeekingAlpha at 2018-11-07 09:22:06:000

The TJX Companies (NYSE: TJX ) -49% . More news on: TJX Companies Inc., MiMedx Group Inc., Infinera Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Akorn misses by $0.13, misses on revenue

via: SeekingAlpha at 2018-11-06 17:29:51:000

Akorn (NASDAQ: AKRX ): Q3 Non-GAAP EPS of -$0.06 misses by $0.13 ; GAAP EPS of -$0.56 misses by $0.42 . More news on: Akorn, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Worst Performing Mid-Cap Stocks In October

via: SeekingAlpha at 2018-11-05 12:33:45:000

In accompanying articles, I have detailed the worst performing decile of the large cap S&P 500 ( SPY ) and the small-cap S&P 600 ( IJR ). This article examines the worst performing 40 stocks in the S&P 400 Mid-Cap ( MDY ). In October 2018, mid-cap stocks had their worst monthly per… read more...

Worst Performing Mid-Cap Stocks In October

via: SeekingAlpha at 2018-11-05 12:33:45:000

In accompanying articles, I have detailed the worst performing decile of the large cap S&P 500 ( SPY ) and the small-cap S&P 600 ( IJR ). This article examines the worst performing 40 stocks in the S&P 400 Mid-Cap ( MDY ). In October 2018, mid-cap stocks had their worst monthly per… read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

FDA approves Akorn's ANDA for Clobetasol Propionate Lotion, 0.05%

via: SeekingAlpha at 2018-10-29 07:30:05:000

Akorn (NASDAQ: AKRX ) has received a new Abbreviated New Drug Application (ANDA) approval from the FDA for Clobetasol Propionate Lotion, 0.05%. More news on: Akorn, Inc., Healthcare stocks news, Read more … read more...

FDA approves Akorn's ANDA for Clobetasol Propionate Lotion, 0.05%

via: SeekingAlpha at 2018-10-29 07:30:05:000

Akorn (NASDAQ: AKRX ) has received a new Abbreviated New Drug Application (ANDA) approval from the FDA for Clobetasol Propionate Lotion, 0.05%. More news on: Akorn, Inc., Healthcare stocks news, Read more … read more...

FDA approves Akorn's ANDA for Clobetasol Propionate Lotion, 0.05%

via: SeekingAlpha at 2018-10-29 07:30:05:000

Akorn (NASDAQ: AKRX ) has received a new Abbreviated New Drug Application (ANDA) approval from the FDA for Clobetasol Propionate Lotion, 0.05%. More news on: Akorn, Inc., Healthcare stocks news, Read more … read more...

Resideo Technologies Set to Join S&P MidCap 400; Akorn to Join S&P SmallCap 600

via: PR Newswire at 2018-10-23 17:56:00:000

NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Resideo Technologies Inc. (NYSE: REZI) will replace Akorn Inc. (NASD: AKRX) in the S&P MidCap 400, and Akorn will replace Big 5 Sporting Goods Corp. (NASD: BGFV) in the S&P SmallCap 600 effective prior to the open of trading on Tuesday, Oc… read more...

Resideo Technologies Set to Join S&P MidCap 400; Akorn to Join S&P SmallCap 600

via: PR Newswire at 2018-10-23 17:56:00:000

NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Resideo Technologies Inc. (NYSE: REZI) will replace Akorn Inc. (NASD: AKRX) in the S&P MidCap 400, and Akorn will replace Big 5 Sporting Goods Corp. (NASD: BGFV) in the S&P SmallCap 600 effective prior to the open of trading on Tuesday, Oc… read more...

Resideo Technologies Set to Join S&P MidCap 400; Akorn to Join S&P SmallCap 600

via: PR Newswire at 2018-10-23 17:56:00:000

NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Resideo Technologies Inc. (NYSE: REZI) will replace Akorn Inc. (NASD: AKRX) in the S&P MidCap 400, and Akorn will replace Big 5 Sporting Goods Corp. (NASD: BGFV) in the S&P SmallCap 600 effective prior to the open of trading on Tuesday, Oc… read more...

Big 5 Sporting Goods slides 3.7% after drop from SmallCap 600

via: SeekingAlpha at 2018-10-23 17:23:52:000

Big 5 Sporting Goods (NASDAQ: BGFV ) is down 3.7% after hours following news that it's exiting the S&P SmallCap 600 , after hanging near the bottom of the index in terms of market cap. More news on: Big 5 Sporting Goods Corporation, Akorn, Inc., Resideo Technologies, Inc., Consumer … read more...

Big 5 Sporting Goods slides 3.7% after drop from SmallCap 600

via: SeekingAlpha at 2018-10-23 17:23:52:000

Big 5 Sporting Goods (NASDAQ: BGFV ) is down 3.7% after hours following news that it's exiting the S&P SmallCap 600 , after hanging near the bottom of the index in terms of market cap. More news on: Big 5 Sporting Goods Corporation, Akorn, Inc., Resideo Technologies, Inc., Consumer … read more...

Big 5 Sporting Goods slides 3.7% after drop from SmallCap 600

via: SeekingAlpha at 2018-10-23 17:23:52:000

Big 5 Sporting Goods (NASDAQ: BGFV ) is down 3.7% after hours following news that it's exiting the S&P SmallCap 600 , after hanging near the bottom of the index in terms of market cap. More news on: Big 5 Sporting Goods Corporation, Akorn, Inc., Resideo Technologies, Inc., Consumer … read more...

Akorn appeals court ruling allowing Fresenius Kabi to exit merger agreement

via: SeekingAlpha at 2018-10-18 14:50:13:000

As expected, Akorn ( AKRX -1.3% ) has filed an appeal with the Delaware Supreme Court of the recent decision by the Delaware Court of Chancery allowing former suitor Fresenius Kabi to walk away from the now-defunct merger. More news on: Akorn, Inc., Healthcare stocks news, Read mor… read more...

Akorn appeals court ruling allowing Fresenius Kabi to exit merger agreement

via: SeekingAlpha at 2018-10-18 14:50:13:000

As expected, Akorn ( AKRX -1.3% ) has filed an appeal with the Delaware Supreme Court of the recent decision by the Delaware Court of Chancery allowing former suitor Fresenius Kabi to walk away from the now-defunct merger. More news on: Akorn, Inc., Healthcare stocks news, Read mor… read more...

Akorn appeals court ruling allowing Fresenius Kabi to exit merger agreement

via: SeekingAlpha at 2018-10-18 14:50:13:000

As expected, Akorn ( AKRX -1.3% ) has filed an appeal with the Delaware Supreme Court of the recent decision by the Delaware Court of Chancery allowing former suitor Fresenius Kabi to walk away from the now-defunct merger. More news on: Akorn, Inc., Healthcare stocks news, Read mor… read more...

RM LAW Announces Investigation of Akorn, Inc.

via: PR Newswire at 2018-10-17 12:15:00:000

BERWYN, Pa. , Oct. 17, 2018 /PRNewswire/ -- RM LAW, P.C. has commenced an investigation into potential securities law violations by certain officers of Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX). If you purchased shares of Akorn and would like to learn more abo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-17 09:10:55:000

AzurRx BioPharma (NASDAQ: AZRX ) initiated with Outperform rating and $6 (140% upside) price target at Oppenheimer. Shares up 8% premarket. More news on: AzurRX Biopharma, Bio-Techne Corp., Bio-Rad Laboratories, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Stock Exchange: Do You Pretend To Understand The Market?

via: SeekingAlpha at 2018-10-12 11:11:50:000

The Stock Exchange is all about trading. Each week we do the following: discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Pretend To Understand The Market?

via: SeekingAlpha at 2018-10-12 11:11:50:000

The Stock Exchange is all about trading. Each week we do the following: discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Pretend To Understand The Market?

via: SeekingAlpha at 2018-10-12 11:11:50:000

The Stock Exchange is all about trading. Each week we do the following: discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Pretend To Understand The Market?

via: SeekingAlpha at 2018-10-12 11:11:50:000

The Stock Exchange is all about trading. Each week we do the following: discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Pretend To Understand The Market?

via: SeekingAlpha at 2018-10-12 11:11:50:000

The Stock Exchange is all about trading. Each week we do the following: discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Robbins Arroyo LLP Is Investigating the Officers and Directors of Akorn, Inc. (AKRX) on Behalf of Shareholders

via: Business Wire at 2018-10-11 17:19:00:000

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Akorn, Inc. (NasdaqGS: AKRX) breached their fiduciary duties to shareholders. In a landmark ruling last week, a Delaware Court determined that Fresenius SE could walk away from its $4…. read more...

Worst-Performing Stocks This Month

via: SeekingAlpha at 2018-10-11 04:23:59:000

The average stock in the S&P 1500 was up 9.24% year-to-date through September, but October has been brutal for stocks thus far. On the surface, the S&P 1500 is only down 1.4% month-to-date, but what lies beneath is much worse. As shown in the chart below, the average stock in the index… read more...

Premarket Gainers as of 9:05 am (10/10/2018)

via: SeekingAlpha at 2018-10-10 09:27:16:000

NVCN +66% on FDA grants Breakthrough Device designation to Neovasc's Reducer. More news on: Neovasc Inc., Novelion Therapeutics, Inc., Esterline Technologies Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Akorn receives ANDA approval for Bimatoprost Ophthalmic Solution

via: SeekingAlpha at 2018-10-10 07:38:27:000

Akorn (NASDAQ: AKRX ) has received a new Abbreviated New Drug Application (ANDA) approval from the FDA for Bimatoprost Ophthalmic Solution, 0.03%. More news on: Akorn, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Merger Arbitrage Mondays - October 8, 2018

via: SeekingAlpha at 2018-10-08 19:16:21:000

Merger activity remained unchanged last week with four new deals announced and seven pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: New Deals: The acquisi… read more...

Merger Arbitrage Mondays - October 8, 2018

via: SeekingAlpha at 2018-10-08 19:16:21:000

Merger activity remained unchanged last week with four new deals announced and seven pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: New Deals: The acquisi… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-04 08:44:27:000

Healthcare Services Group (NASDAQ: HCSG ) initiated with Hold rating and $40 (flat) price target at Berenberg. More news on: Healthcare Services Group, Inc., Syneos Health, Inc., Akorn, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-04 08:44:27:000

Healthcare Services Group (NASDAQ: HCSG ) initiated with Hold rating and $40 (flat) price target at Berenberg. More news on: Healthcare Services Group, Inc., Syneos Health, Inc., Akorn, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-04 08:44:27:000

Healthcare Services Group (NASDAQ: HCSG ) initiated with Hold rating and $40 (flat) price target at Berenberg. More news on: Healthcare Services Group, Inc., Syneos Health, Inc., Akorn, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Generics in the green following proposed favorable guidance from FDA

via: SeekingAlpha at 2018-10-02 14:03:56:000

Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...

Generics in the green following proposed favorable guidance from FDA

via: SeekingAlpha at 2018-10-02 14:03:56:000

Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-02 07:30:09:000

National Vision (NASDAQ: EYE ) initiated with Equal Weight rating and $50 (12% upside) price target at Barclays. More news on: National Vision Holdings, Inovio Pharmaceuticals, Inc., Theratechnologies Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-02 07:30:09:000

National Vision (NASDAQ: EYE ) initiated with Equal Weight rating and $50 (12% upside) price target at Barclays. More news on: National Vision Holdings, Inovio Pharmaceuticals, Inc., Theratechnologies Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Merger Arbitrage Mondays - October 1, 2018

via: SeekingAlpha at 2018-10-01 21:42:42:000

Merger activity decreased last week with four new deals announced and two pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: New Deals: The acquisition of Randgol… read more...

Merger Arbitrage Mondays - October 1, 2018

via: SeekingAlpha at 2018-10-01 21:42:42:000

Merger activity decreased last week with four new deals announced and two pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: New Deals: The acquisition of Randgol… read more...

Midday Gainers / Losers (10/01/2018)

via: SeekingAlpha at 2018-10-01 12:40:08:000

Gainers: OGEN +51% . LEVB +37% . NBEV +39% . ARCW +30% . NTGN +27% . IGC +25% . IFMK +24% . ACST +21% . ATLC +21% . ALT +21% . More news on: Oragenics, Inc., Level Brands, Inc., New Age Beverages Corporation, Stocks on the move, , Read more … read more...

Akorn Comments on Delaware Chancery Court Ruling

via: Business Wire at 2018-10-01 09:25:00:000

Akorn, Inc. (NASDAQ:AKRX), today issued the following statement in response to the ruling by the Delaware Chancery Court on the complaint filed by Akorn against Fresenius Kabi AG: We are disappointed by the ruling by the Delaware Chancery Court determining not to force Fresenius … read more...

Akorn down 47% premarket, trading suspended pending news

via: SeekingAlpha at 2018-10-01 08:31:09:000

Nasdaq has suspended trading in Akorn (NASDAQ: AKRX ) pending the release of news. Shares were down 47% at the time. More news on: Akorn, Inc., Fresenius Medical Care AG & Co. KGAA, Healthcare stocks news, Stocks on the move, Read more … read more...

Merger Arbitrage Mondays - September 24, 2018

via: SeekingAlpha at 2018-09-25 10:39:00:000

Merger activity increased last week with nine new deals announced and two pending deals closing. For folks who were long SteadyMed (STDY), brokers have started sending out letters with the form you can fill out to make sure 25% of the amount due is not withheld for taxes according to Israeli l… read more...

Merger Arbitrage Mondays - September 24, 2018

via: SeekingAlpha at 2018-09-25 10:39:00:000

Merger activity increased last week with nine new deals announced and two pending deals closing. For folks who were long SteadyMed (STDY), brokers have started sending out letters with the form you can fill out to make sure 25% of the amount due is not withheld for taxes according to Israeli l… read more...

Merger Arbitrage Mondays - September 24, 2018

via: SeekingAlpha at 2018-09-25 10:39:00:000

Merger activity increased last week with nine new deals announced and two pending deals closing. For folks who were long SteadyMed (STDY), brokers have started sending out letters with the form you can fill out to make sure 25% of the amount due is not withheld for taxes according to Israeli l… read more...

Nostrum Labs hikes price of mature antibiotic 400%

via: SeekingAlpha at 2018-09-12 11:50:15:000

In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical… read more...

Nostrum Labs hikes price of mature antibiotic 400%

via: SeekingAlpha at 2018-09-12 11:50:15:000

In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical… read more...

Nostrum Labs hikes price of mature antibiotic 400%

via: SeekingAlpha at 2018-09-12 11:50:15:000

In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical… read more...

Stock Exchange: Do You Buy At All Time Highs?

via: SeekingAlpha at 2018-09-07 06:43:40:000

The Stock Exchange is all about trading. Each week we do the following: Discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Buy At All Time Highs?

via: SeekingAlpha at 2018-09-07 06:43:40:000

The Stock Exchange is all about trading. Each week we do the following: Discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Buy At All Time Highs?

via: SeekingAlpha at 2018-09-07 06:43:40:000

The Stock Exchange is all about trading. Each week we do the following: Discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Buy At All Time Highs?

via: SeekingAlpha at 2018-09-07 06:43:40:000

The Stock Exchange is all about trading. Each week we do the following: Discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Stock Exchange: Do You Buy At All Time Highs?

via: SeekingAlpha at 2018-09-07 06:43:40:000

The Stock Exchange is all about trading. Each week we do the following: Discuss an important issue for traders; highlight several technical trading methods, including current ideas; feature advice from top traders and writers; and, provide a few (minority) reactions from fundamenta… read more...

Merger Arbitrage Mondays - September 3, 2018

via: SeekingAlpha at 2018-09-04 04:10:49:000

Merger activity remained unchanged last week with three new deals announced and three pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. There were two new deals announced in the Deals i… read more...

Merger Arbitrage Mondays - September 3, 2018

via: SeekingAlpha at 2018-09-04 04:10:49:000

Merger activity remained unchanged last week with three new deals announced and three pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. There were two new deals announced in the Deals i… read more...

Merger Arbitrage Mondays - September 3, 2018

via: SeekingAlpha at 2018-09-04 04:10:49:000

Merger activity remained unchanged last week with three new deals announced and three pending deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. There were two new deals announced in the Deals i… read more...

Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-02 14:57:04:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulsons 13F stock portfolio on a quarterly basis. It is based on Paulsons regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulsons Paulson & Co… read more...

Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-02 14:57:04:000

This article is part of a series that provides an ongoing analysis of the changes made to John Paulsons 13F stock portfolio on a quarterly basis. It is based on Paulsons regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulsons Paulson & Co… read more...

Akorn down 16% as hearing ends

via: SeekingAlpha at 2018-08-23 15:06:16:000

"Nobody should think they have a clean winner here," says the judge in the Akorn/Fresnius trial. More news on: Akorn, Inc., Fresenius Medical Care AG & Co. KGAA, Fresenius SE & Co. KGaA ADR, Merger & acquisition news, Healthcare stocks news, Stocks on the move, Read more ….. read more...

Akorn down 16% as hearing ends

via: SeekingAlpha at 2018-08-23 15:06:16:000

"Nobody should think they have a clean winner here," says the judge in the Akorn/Fresnius trial. More news on: Akorn, Inc., Fresenius Medical Care AG & Co. KGAA, Fresenius SE & Co. KGaA ADR, Merger & acquisition news, Healthcare stocks news, Stocks on the move, Read more ….. read more...

Akorn down 16% as hearing ends

via: SeekingAlpha at 2018-08-23 15:06:16:000

"Nobody should think they have a clean winner here," says the judge in the Akorn/Fresnius trial. More news on: Akorn, Inc., Fresenius Medical Care AG & Co. KGAA, Fresenius SE & Co. KGaA ADR, Merger & acquisition news, Healthcare stocks news, Stocks on the move, Read more ….. read more...

Akorn down 12% ahead of hearing on disputed Fresenius merger

via: SeekingAlpha at 2018-08-23 12:43:58:000

Investors are behaving like they expect bad news from today's post-trial hearing in Delaware related to Akorn's ( AKRX -11.7% ) dispute with former merger partner Fresenius Medical Care ( FMS -0.1% ) after the latter backed out of the $4.75B deal. Shares have retraced 17% thi… read more...

Akorn down 12% ahead of hearing on disputed Fresenius merger

via: SeekingAlpha at 2018-08-23 12:43:58:000

Investors are behaving like they expect bad news from today's post-trial hearing in Delaware related to Akorn's ( AKRX -11.7% ) dispute with former merger partner Fresenius Medical Care ( FMS -0.1% ) after the latter backed out of the $4.75B deal. Shares have retraced 17% thi… read more...

Akorn down 12% ahead of hearing on disputed Fresenius merger

via: SeekingAlpha at 2018-08-23 12:43:58:000

Investors are behaving like they expect bad news from today's post-trial hearing in Delaware related to Akorn's ( AKRX -11.7% ) dispute with former merger partner Fresenius Medical Care ( FMS -0.1% ) after the latter backed out of the $4.75B deal. Shares have retraced 17% thi… read more...

Midday Gainers / Losers (08/23/2018)

via: SeekingAlpha at 2018-08-23 12:40:15:000

Gainers: OBLN +45% . LEJU +27% . LX +24% . REED +17% . WSM +15% . SSC +13% . INSG +13% . DHX +13% . RAVN +12% . MOXC +11% . Losers: HMNY -27% . CATO -18% . PAVM -16% . LB -13% . YECO -7% . SMRT -13% . SYN -11% . AKRX -12% . CKPT … read more...

Midday Gainers / Losers (08/23/2018)

via: SeekingAlpha at 2018-08-23 12:40:15:000

Gainers: OBLN +45% . LEJU +27% . LX +24% . REED +17% . WSM +15% . SSC +13% . INSG +13% . DHX +13% . RAVN +12% . MOXC +11% . Losers: HMNY -27% . CATO -18% . PAVM -16% . LB -13% . YECO -7% . SMRT -13% . SYN -11% . AKRX -12% . CKPT … read more...

Midday Gainers / Losers (08/23/2018)

via: SeekingAlpha at 2018-08-23 12:40:15:000

Gainers: OBLN +45% . LEJU +27% . LX +24% . REED +17% . WSM +15% . SSC +13% . INSG +13% . DHX +13% . RAVN +12% . MOXC +11% . Losers: HMNY -27% . CATO -18% . PAVM -16% . LB -13% . YECO -7% . SMRT -13% . SYN -11% . AKRX -12% . CKPT … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-23 08:21:11:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-23 08:21:11:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-23 08:21:11:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Overweight rating and $25 (79% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Halozyme Therapeutics, Inc., Healthcare stocks news,… read more...

FDA OKs first generic drug under new accelerated pathway

via: SeekingAlpha at 2018-08-08 11:38:38:000

The FDA has approved Apotex's potassium chloride oral solution for the treatment and prevention of hypokalemia (low blood potassium) in patients on diuretics and when dietary management with potassium-rich foods is inadequate or diuretic dose reduction is not possible. More news on: Myla… read more...

FDA OKs first generic drug under new accelerated pathway

via: SeekingAlpha at 2018-08-08 11:38:38:000

The FDA has approved Apotex's potassium chloride oral solution for the treatment and prevention of hypokalemia (low blood potassium) in patients on diuretics and when dietary management with potassium-rich foods is inadequate or diuretic dose reduction is not possible. More news on: Myla… read more...

FDA OKs first generic drug under new accelerated pathway

via: SeekingAlpha at 2018-08-08 11:38:38:000

The FDA has approved Apotex's potassium chloride oral solution for the treatment and prevention of hypokalemia (low blood potassium) in patients on diuretics and when dietary management with potassium-rich foods is inadequate or diuretic dose reduction is not possible. More news on: Myla… read more...

Mylan's trimmed guidance may pressure generic drug makers

via: SeekingAlpha at 2018-08-08 09:07:22:000

Mylan (NASDAQ: MYL ) is under modest pressure premarket, down 5% on average volume, after cutting its 2018 guidance due to continued challenges in the U.S. market, a move that could stoke selling in the generics space. More news on: Mylan Inc, Teva Pharmaceutical Industries Lim… read more...

Mylan's trimmed guidance may pressure generic drug makers

via: SeekingAlpha at 2018-08-08 09:07:22:000

Mylan (NASDAQ: MYL ) is under modest pressure premarket, down 5% on average volume, after cutting its 2018 guidance due to continued challenges in the U.S. market, a move that could stoke selling in the generics space. More news on: Mylan Inc, Teva Pharmaceutical Industries Lim… read more...

Mylan's trimmed guidance may pressure generic drug makers

via: SeekingAlpha at 2018-08-08 09:07:22:000

Mylan (NASDAQ: MYL ) is under modest pressure premarket, down 5% on average volume, after cutting its 2018 guidance due to continued challenges in the U.S. market, a move that could stoke selling in the generics space. More news on: Mylan Inc, Teva Pharmaceutical Industries Lim… read more...

The Idea Guide: Tech And Contrarian Ideas In The Spotlight

via: SeekingAlpha at 2018-07-25 15:32:27:000

Welcome to the Idea Guide! This is the first edition of this article that is exclusive to PRO and PRO+ subscribers. What is the Idea Guide? It's a twice weekly review of the articles we publish on Seeking Alpha to highlight interesting long and short ideas, as well as underlying lessons and … read more...

The Idea Guide: Tech And Contrarian Ideas In The Spotlight

via: SeekingAlpha at 2018-07-25 15:32:27:000

Welcome to the Idea Guide! This is the first edition of this article that is exclusive to PRO and PRO+ subscribers. What is the Idea Guide? It's a twice weekly review of the articles we publish on Seeking Alpha to highlight interesting long and short ideas, as well as underlying lessons and … read more...

The Idea Guide: Tech And Contrarian Ideas In The Spotlight

via: SeekingAlpha at 2018-07-25 15:32:27:000

Welcome to the Idea Guide! This is the first edition of this article that is exclusive to PRO and PRO+ subscribers. What is the Idea Guide? It's a twice weekly review of the articles we publish on Seeking Alpha to highlight interesting long and short ideas, as well as underlying lessons and … read more...

Akorn V. Fresenius - Post Trial Thoughts

via: SeekingAlpha at 2018-07-20 12:51:11:000

AKRX Trial Recap Where do we go from Here? AKRX and Fresenius kicked off in DE Court from July 9 th July 13 th in front of Judge Laster. During the week of testimony there were some interesting developments with each side making its case. In the rest of this article I w… read more...

Akorn V. Fresenius - Post Trial Thoughts

via: SeekingAlpha at 2018-07-20 12:51:11:000

AKRX Trial Recap Where do we go from Here? AKRX and Fresenius kicked off in DE Court from July 9 th July 13 th in front of Judge Laster. During the week of testimony there were some interesting developments with each side making its case. In the rest of this article I w… read more...

Akorn V. Fresenius - Post Trial Thoughts

via: SeekingAlpha at 2018-07-20 12:51:11:000

AKRX Trial Recap Where do we go from Here? AKRX and Fresenius kicked off in DE Court from July 9 th July 13 th in front of Judge Laster. During the week of testimony there were some interesting developments with each side making its case. In the rest of this article I w… read more...

Akorn V. Fresenius - Post Trial Thoughts

via: SeekingAlpha at 2018-07-20 12:51:11:000

AKRX Trial Recap Where do we go from Here? AKRX and Fresenius kicked off in DE Court from July 9 th July 13 th in front of Judge Laster. During the week of testimony there were some interesting developments with each side making its case. In the rest of this article I w… read more...

Akorn V. Fresenius - Post Trial Thoughts

via: SeekingAlpha at 2018-07-20 12:51:11:000

AKRX Trial Recap Where do we go from Here? AKRX and Fresenius kicked off in DE Court from July 9 th July 13 th in front of Judge Laster. During the week of testimony there were some interesting developments with each side making its case. In the rest of this article I w… read more...

Merger Arbitrage Mondays - July 16, 2018

via: SeekingAlpha at 2018-07-16 08:15:22:000

Merger activity decreased last week with two new deals announced. You can find all the active deals listed below in our Merger Arbitrage Tool ((MAT)) that automatically updates itself during market hours. There were three new deals announced in the Deals in the Works section. Deal Statist… read more...

Merger Arbitrage Mondays - July 16, 2018

via: SeekingAlpha at 2018-07-16 08:15:22:000

Merger activity decreased last week with two new deals announced. You can find all the active deals listed below in our Merger Arbitrage Tool ((MAT)) that automatically updates itself during market hours. There were three new deals announced in the Deals in the Works section. Deal Statist… read more...

Merger Arbitrage Mondays - July 16, 2018

via: SeekingAlpha at 2018-07-16 08:15:22:000

Merger activity decreased last week with two new deals announced. You can find all the active deals listed below in our Merger Arbitrage Tool ((MAT)) that automatically updates itself during market hours. There were three new deals announced in the Deals in the Works section. Deal Statist… read more...

Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

via: SeekingAlpha at 2018-07-16 04:51:47:000

With Activist Pressure Mounting, Allergan Will Need Positive Results from Upcoming Catalysts Allergan (AGN) is sitting at a crucial period in the company's history. The stock has declined by over 45% since its peak in 2015, and activist shareholders have begun to get more involved with publi… read more...

Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

via: SeekingAlpha at 2018-07-16 04:51:47:000

With Activist Pressure Mounting, Allergan Will Need Positive Results from Upcoming Catalysts Allergan (AGN) is sitting at a crucial period in the company's history. The stock has declined by over 45% since its peak in 2015, and activist shareholders have begun to get more involved with publi… read more...

Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts

via: SeekingAlpha at 2018-07-16 04:51:47:000

With Activist Pressure Mounting, Allergan Will Need Positive Results from Upcoming Catalysts Allergan (AGN) is sitting at a crucial period in the company's history. The stock has declined by over 45% since its peak in 2015, and activist shareholders have begun to get more involved with publi… read more...

Akorn rallies ahead of Fresenius trial

via: SeekingAlpha at 2018-07-06 07:28:06:000

Akorn (NASDAQ: AKRX ) has jumped almost 10% in a week ahead of Monday's start of its trial with Fresenius in a Delaware court. The company sued the German medical supplies firm after it backed out of its $4.75B merger with the generic drug maker over allegations the latter defrau… read more...

Akorn rallies ahead of Fresenius trial

via: SeekingAlpha at 2018-07-06 07:28:06:000

Akorn (NASDAQ: AKRX ) has jumped almost 10% in a week ahead of Monday's start of its trial with Fresenius in a Delaware court. The company sued the German medical supplies firm after it backed out of its $4.75B merger with the generic drug maker over allegations the latter defrau… read more...

Akorn rallies ahead of Fresenius trial

via: SeekingAlpha at 2018-07-06 07:28:06:000

Akorn (NASDAQ: AKRX ) has jumped almost 10% in a week ahead of Monday's start of its trial with Fresenius in a Delaware court. The company sued the German medical supplies firm after it backed out of its $4.75B merger with the generic drug maker over allegations the latter defrau… read more...

Akorn rallies ahead of Fresenius trial

via: SeekingAlpha at 2018-07-06 07:28:06:000

Akorn (NASDAQ: AKRX ) has jumped almost 10% in a week ahead of Monday's start of its trial with Fresenius in a Delaware court. The company sued the German medical supplies firm after it backed out of its $4.75B merger with the generic drug maker over allegations the latter defrau… read more...

Akorn rallies ahead of Fresenius trial

via: SeekingAlpha at 2018-07-06 07:28:06:000

Akorn (NASDAQ: AKRX ) has jumped almost 10% in a week ahead of Monday's start of its trial with Fresenius in a Delaware court. The company sued the German medical supplies firm after it backed out of its $4.75B merger with the generic drug maker over allegations the latter defrau… read more...

Merger Arbitrage Mondays - July 2, 2018

via: SeekingAlpha at 2018-07-02 09:36:58:000

Merger activity decreased last week with six new deals announced. The second of the three semiconductor deals that had large spreads because of concerns that Chinese regulators might not approve the deal, received Chinese regulatory approval last week. The acquisition of Cavium ( CAVM ) by Mar… read more...

Merger Arbitrage Mondays - July 2, 2018

via: SeekingAlpha at 2018-07-02 09:36:58:000

Merger activity decreased last week with six new deals announced. The second of the three semiconductor deals that had large spreads because of concerns that Chinese regulators might not approve the deal, received Chinese regulatory approval last week. The acquisition of Cavium ( CAVM ) by Mar… read more...

Merger Arbitrage Mondays - July 2, 2018

via: SeekingAlpha at 2018-07-02 09:36:58:000

Merger activity decreased last week with six new deals announced. The second of the three semiconductor deals that had large spreads because of concerns that Chinese regulators might not approve the deal, received Chinese regulatory approval last week. The acquisition of Cavium ( CAVM ) by Mar… read more...

Merger Arbitrage Mondays - June 18, 2018

via: SeekingAlpha at 2018-06-19 08:13:12:000

Merger activity increased last week with two new deals announced and five pending deals closing. Several deals with large spreads on account of regulatory hurdles including Bayer's acquisition of Monsanto, AT&T's (T) acquisition of Time Warner and China Oceanwide's acquisition of Genworth … read more...

Merger Arbitrage Mondays - June 18, 2018

via: SeekingAlpha at 2018-06-19 08:13:12:000

Merger activity increased last week with two new deals announced and five pending deals closing. Several deals with large spreads on account of regulatory hurdles including Bayer's acquisition of Monsanto, AT&T's (T) acquisition of Time Warner and China Oceanwide's acquisition of Genworth … read more...

Merger Arbitrage Mondays - June 18, 2018

via: SeekingAlpha at 2018-06-19 08:13:12:000

Merger activity increased last week with two new deals announced and five pending deals closing. Several deals with large spreads on account of regulatory hurdles including Bayer's acquisition of Monsanto, AT&T's (T) acquisition of Time Warner and China Oceanwide's acquisition of Genworth … read more...

With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis

via: SeekingAlpha at 2018-06-13 17:32:45:000

Over the last year, Mylan ( MYL ) has faced a difficult generic environment but has managed to offset the pressure with the launch of its generic Copaxone and a strong ex-US business that has helped stabilize the business. The key topics around the stock are now: 1) Neulasta biosimilar appro… read more...

With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis

via: SeekingAlpha at 2018-06-13 17:32:45:000

Over the last year, Mylan ( MYL ) has faced a difficult generic environment but has managed to offset the pressure with the launch of its generic Copaxone and a strong ex-US business that has helped stabilize the business. The key topics around the stock are now: 1) Neulasta biosimilar appro… read more...

With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis

via: SeekingAlpha at 2018-06-13 17:32:45:000

Over the last year, Mylan ( MYL ) has faced a difficult generic environment but has managed to offset the pressure with the launch of its generic Copaxone and a strong ex-US business that has helped stabilize the business. The key topics around the stock are now: 1) Neulasta biosimilar appro… read more...

Akorn And Fresenius: Merger Arbitrage

via: SeekingAlpha at 2018-06-08 05:00:00:000

Summary Thesis: The odds of the Akorn ( AKRX) deal closing are higher than the probability currently ascribed by market prices (~30%). Downside could be potentially ugly if Fresenius (FSNUF) (FSNUY) is able to walk away, but you are adequately compensated with upside of >80% if th… read more...

Akorn And Fresenius: Merger Arbitrage

via: SeekingAlpha at 2018-06-08 05:00:00:000

Summary Thesis: The odds of the Akorn ( AKRX) deal closing are higher than the probability currently ascribed by market prices (~30%). Downside could be potentially ugly if Fresenius (FSNUF) (FSNUY) is able to walk away, but you are adequately compensated with upside of >80% if th… read more...

Akorn And Fresenius: Merger Arbitrage

via: SeekingAlpha at 2018-06-08 05:00:00:000

Summary Thesis: The odds of the Akorn ( AKRX) deal closing are higher than the probability currently ascribed by market prices (~30%). Downside could be potentially ugly if Fresenius (FSNUF) (FSNUY) is able to walk away, but you are adequately compensated with upside of >80% if th… read more...

Akorn And Fresenius: Merger Arbitrage

via: SeekingAlpha at 2018-06-08 05:00:00:000

Summary Thesis: The odds of the Akorn ( AKRX) deal closing are higher than the probability currently ascribed by market prices (~30%). Downside could be potentially ugly if Fresenius (FSNUF) (FSNUY) is able to walk away, but you are adequately compensated with upside of >80% if th… read more...

Akorn And Fresenius: Merger Arbitrage

via: SeekingAlpha at 2018-06-08 05:00:00:000

Summary Thesis: The odds of the Akorn ( AKRX) deal closing are higher than the probability currently ascribed by market prices (~30%). Downside could be potentially ugly if Fresenius (FSNUF) (FSNUY) is able to walk away, but you are adequately compensated with upside of >80% if th… read more...

FDA issues draft guidance aimed at easing regulatory path for generic drugs

via: SeekingAlpha at 2018-05-31 11:27:37:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. announces draft guidance aimed at curtailing behavior by branded drug makers to delay competition from generics. More news on: iShares U.S. Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, Heal… read more...

FDA issues draft guidance aimed at easing regulatory path for generic drugs

via: SeekingAlpha at 2018-05-31 11:27:37:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. announces draft guidance aimed at curtailing behavior by branded drug makers to delay competition from generics. More news on: iShares U.S. Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, Heal… read more...

FDA issues draft guidance aimed at easing regulatory path for generic drugs

via: SeekingAlpha at 2018-05-31 11:27:37:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. announces draft guidance aimed at curtailing behavior by branded drug makers to delay competition from generics. More news on: iShares U.S. Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, Heal… read more...

Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.

via: PR Newswire at 2018-05-29 15:31:00:000

NEW YORK , May 29, 2018 /PRNewswire/ --Moore Kuehn, PLLC is investigating potential claims for breach of fiduciary duty involving the directors and officers of Akorn, Inc. (NASDAQ: AKRX ). On February 26, 2018 Fresenius SE & Co. KGaA ("Fresenius") announced it is conduc… read more...

Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.

via: PR Newswire at 2018-05-29 15:31:00:000

NEW YORK , May 29, 2018 /PRNewswire/ --Moore Kuehn, PLLC is investigating potential claims for breach of fiduciary duty involving the directors and officers of Akorn, Inc. (NASDAQ: AKRX ). On February 26, 2018 Fresenius SE & Co. KGaA ("Fresenius") announced it is conduc… read more...

Moore Kuehn, PLLC Announces an Investigation Involving Possible Breaches of Fiduciary Duties by Officers and Directors of Akorn, Inc.

via: PR Newswire at 2018-05-29 15:31:00:000

NEW YORK , May 29, 2018 /PRNewswire/ --Moore Kuehn, PLLC is investigating potential claims for breach of fiduciary duty involving the directors and officers of Akorn, Inc. (NASDAQ: AKRX ). On February 26, 2018 Fresenius SE & Co. KGaA ("Fresenius") announced it is conduc… read more...

SA Interview: Event-Driven Investing With Donostia

via: SeekingAlpha at 2018-05-13 07:30:00:000

Feature interview Donostia is an analyst at an event-driven hedge fund who focuses on long/short ideas across the capital structure. We emailed with Donostia about how regulators have changed their definition of competition as part of antitrust review, how merger arb returns should be me… read more...

SA Interview: Event-Driven Investing With Donostia

via: SeekingAlpha at 2018-05-13 07:30:00:000

Feature interview Donostia is an analyst at an event-driven hedge fund who focuses on long/short ideas across the capital structure. We emailed with Donostia about how regulators have changed their definition of competition as part of antitrust review, how merger arb returns should be me… read more...

Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data

via: SeekingAlpha at 2018-05-04 08:01:00:000

Analysis focus: AKAO So, the FDA Ad Com finally backed Achaogens (AKAO) plazomicin! While that is good that the committee voted 15-0 (1 abstain) in favor of the cUTI indication, it is not so good that they also voted 11-4 (1 abstain) that that the the data failed to provide subst… read more...

Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data

via: SeekingAlpha at 2018-05-04 08:01:00:000

Analysis focus: AKAO So, the FDA Ad Com finally backed Achaogens (AKAO) plazomicin! While that is good that the committee voted 15-0 (1 abstain) in favor of the cUTI indication, it is not so good that they also voted 11-4 (1 abstain) that that the the data failed to provide subst… read more...

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX

via: Business Wire at 2018-05-02 23:48:00:000

Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. (Akorn or the Company) (NASDAQ: AKRX) and certain of its officers. The class action, filed in United States District Court, for the District of Illinois, Eastern Division, i… read more...

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX

via: Business Wire at 2018-05-02 23:48:00:000

Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. (Akorn or the Company) (NASDAQ: AKRX) and certain of its officers. The class action, filed in United States District Court, for the District of Illinois, Eastern Division, i… read more...

Akorn down 8% on Fresenius claim of fraudulent azithromycin data

via: SeekingAlpha at 2018-05-02 11:36:33:000

Akorn ( AKRX -7.8% ) slumps on double normal volume on the heels of a Bloomberg report that former suitor Fresenius Medical Care ( FMS +2.4% ) disclosed in court that its investigation found that an Akorn executive intentionally submitted fraudulent azithromycin data to the FDA in 2012, … read more...

Akorn down 8% on Fresenius claim of fraudulent azithromycin data

via: SeekingAlpha at 2018-05-02 11:36:33:000

Akorn ( AKRX -7.8% ) slumps on double normal volume on the heels of a Bloomberg report that former suitor Fresenius Medical Care ( FMS +2.4% ) disclosed in court that its investigation found that an Akorn executive intentionally submitted fraudulent azithromycin data to the FDA in 2012, … read more...

Reviewing The Akorn-Fresenius Merger Fallout

via: SeekingAlpha at 2018-05-02 08:53:23:000

Background On April 22, 2018 Fresenius SE & Co. abandoned its offer to acquire Akorn, Inc. (NASDAQ: AKRX ) after having agreed in 2017 to acquire the company for about $4.75 billion ($34/share). This came after Fresenius said in February that it could terminate the deal if its own ind… read more...

Reviewing The Akorn-Fresenius Merger Fallout

via: SeekingAlpha at 2018-05-02 08:53:23:000

Background On April 22, 2018 Fresenius SE & Co. abandoned its offer to acquire Akorn, Inc. (NASDAQ: AKRX ) after having agreed in 2017 to acquire the company for about $4.75 billion ($34/share). This came after Fresenius said in February that it could terminate the deal if its own ind… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Your Daily Pharma Scoop: Akorn Revives, Eloxx Secondary, Celyad Moves Up

via: SeekingAlpha at 2018-04-30 08:00:00:000

Analysis focus: Akorn Akorn Therapeutics (AKRX) has gained considerably on hopes that it will, after all, reach a buyout deal with Fresenius (FMS). The $4.75bn deal has been going through some rough patch after Fresenius pulled out of the deal last week. Trouble began in late February wh… read more...

Akorn up 9% on hopes of Fresenius deal

via: SeekingAlpha at 2018-04-27 13:55:03:000

Akorn ( AKRX +8.6% ) is up on more than double normal volume on optimism that its on-the-rocks acquisition by Fresenius Medical Care ( FMS +0.8% ) may still go through. More news on: Akorn, Inc., Fresenius Medical Care AG & Co. KGAA, Healthcare stocks news, Merger & acquisition… read more...

Akorn up 9% on hopes of Fresenius deal

via: SeekingAlpha at 2018-04-27 13:55:03:000

Akorn ( AKRX +8.6% ) is up on more than double normal volume on optimism that its on-the-rocks acquisition by Fresenius Medical Care ( FMS +0.8% ) may still go through. More news on: Akorn, Inc., Fresenius Medical Care AG & Co. KGAA, Healthcare stocks news, Merger & acquisition… read more...

Lifshitz & Miller LLP Announces Investigation of Acadia Healthcare Company, Inc., Akorn, Inc., Blackhawk Network Holdings, Inc., Facebook, Inc., IZEA Inc., MuleSoft, Inc., Solid Biosciences Inc., and Tableau Software, Inc.

via: PR Newswire at 2018-04-24 13:46:00:000

NEW YORK , April 24, 2018 /PRNewswire/ -- Acadia Healthcare Company, Inc. (ACHC) Lifshitz & Miller announces investigation into possible securities law violations in connection with Acadia's reduction in revenue guidance for fiscal year 2017. If you are an Acadia invest… read more...

Lifshitz & Miller LLP Announces Investigation of Acadia Healthcare Company, Inc., Akorn, Inc., Blackhawk Network Holdings, Inc., Facebook, Inc., IZEA Inc., MuleSoft, Inc., Solid Biosciences Inc., and Tableau Software, Inc.

via: PR Newswire at 2018-04-24 13:46:00:000

NEW YORK , April 24, 2018 /PRNewswire/ -- Acadia Healthcare Company, Inc. (ACHC) Lifshitz & Miller announces investigation into possible securities law violations in connection with Acadia's reduction in revenue guidance for fiscal year 2017. If you are an Acadia invest… read more...

AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Akorn, Inc.To Contact The Firm

via: Business Wire at 2018-04-23 17:29:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akorn, Inc. (Akorn or the Company) (NASDAQ:AKRX) of the May 7, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed agai… read more...

AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Akorn, Inc.To Contact The Firm

via: Business Wire at 2018-04-23 17:29:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akorn, Inc. (Akorn or the Company) (NASDAQ:AKRX) of the May 7, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed agai… read more...

Midday Gainers / Losers (04/23/2018)

via: SeekingAlpha at 2018-04-23 12:45:24:000

Gainers: CHEK +27% . OASM +14% . NLS +13% . MDR +13% . ABCD +13% . FRSX +13% . TSG +11% . JOB +11% . PVTL +11% . EDGE +11% . More news on: Check-Cap Ltd., Oasmia Pharmaceutical, Nautilus, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (04/23/2018)

via: SeekingAlpha at 2018-04-23 12:45:24:000

Gainers: CHEK +27% . OASM +14% . NLS +13% . MDR +13% . ABCD +13% . FRSX +13% . TSG +11% . JOB +11% . PVTL +11% . EDGE +11% . More news on: Check-Cap Ltd., Oasmia Pharmaceutical, Nautilus, Inc., Stocks on the move, , Read more … read more...

AKRX Investor Alert: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals (NASDAQ: AKRX) Investors

via: PR Newswire at 2018-02-09 08:03:00:000

BOSTON , Feb. 9, 2018 /PRNewswire/ --Kyros Law Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ: AKRX) that it is filing legal claims on behalf of investors against the company for possible securities fraud violations.. Akorn Pharmaceuticals (NASDAQ: AKRX) investors… read more...

AKRX Investor Alert: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals (NASDAQ: AKRX) Investors

via: PR Newswire at 2018-02-09 08:03:00:000

BOSTON , Feb. 9, 2018 /PRNewswire/ --Kyros Law Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ: AKRX) that it is filing legal claims on behalf of investors against the company for possible securities fraud violations.. Akorn Pharmaceuticals (NASDAQ: AKRX) investors… read more...

AKRX Investor Alert: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals (NASDAQ: AKRX) Investors

via: PR Newswire at 2018-02-09 08:03:00:000

BOSTON , Feb. 9, 2018 /PRNewswire/ --Kyros Law Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ: AKRX) that it is filing legal claims on behalf of investors against the company for possible securities fraud violations.. Akorn Pharmaceuticals (NASDAQ: AKRX) investors… read more...

AKRX Investor Alert: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals (NASDAQ: AKRX) Investors

via: PR Newswire at 2018-02-09 08:03:00:000

BOSTON , Feb. 9, 2018 /PRNewswire/ --Kyros Law Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ: AKRX) that it is filing legal claims on behalf of investors against the company for possible securities fraud violations.. Akorn Pharmaceuticals (NASDAQ: AKRX) investors… read more...

AKRX Investor Alert: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals (NASDAQ: AKRX) Investors

via: PR Newswire at 2018-02-09 08:03:00:000

BOSTON , Feb. 9, 2018 /PRNewswire/ --Kyros Law Offices is alerting investors of Akorn Pharmaceuticals (NASDAQ: AKRX) that it is filing legal claims on behalf of investors against the company for possible securities fraud violations.. Akorn Pharmaceuticals (NASDAQ: AKRX) investors… read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2018-01-26 13:09:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2018-01-26 13:09:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2018-01-26 13:09:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2018-01-26 13:09:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2018-01-26 13:09:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2018-01-26 13:09:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

U.S. Justice Department may seek damages from generic drugmakers for price-fixing

via: SeekingAlpha at 2018-01-19 13:16:00:000

Some generic drug firms are under modest pressure in apparent response to a speech delivered by U.S. Department of Justice antitrust division chief Makan Delrahim earlier today at George Mason University's law school. He said the DOJ may sue generic drug companies to recover damages over all… read more...

Wall Street Breakfast: Investors Calm As Government Shutdown Looms

via: SeekingAlpha at 2018-01-19 07:01:29:000

Markets appear to be shrugging off the potential for a government shutdown as traders are reminded that nearly $6.9T has been added to the U.S. stock market cap over the last year (President Trump will celebrate his inauguration anniversary tomorrow). Though House Republicans have v… read more...

Generic firms under pressure on possible hospital drug-making venture

via: SeekingAlpha at 2018-01-18 10:06:04:000

Generic drug makers are under pressure in early trading on the heels of a New York Times article about hospital groups' plans to establish a non-profit drug company aimed at supplying certain generic drugs at affordable prices. More news on: Amphastar, ANI Pharmaceuticals, Inc., Aclaris Th… read more...

Hospital groups planning to enter generic drugs business

via: SeekingAlpha at 2018-01-18 08:21:15:000

The NYT reports that some U.S. hospital systems are planning to enter the generic drugs business in an effort to preserve the supply of key off-patent medicines at affordable prices. About 300 hospitals, led by Utah-based Intermountain Healthcare, are on board with more to follow. More n… read more...

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc.

via: PR Newswire at 2018-01-18 08:00:00:000

ROCKFORD, Ill. , Jan. 18, 2018 /PRNewswire/ -- UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR ACQUIRED SHARES OF AKORN INC.'S(NASDAQ:AKRX)COMMON STOCK BETWEEN MAY … read more...

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc.

via: PR Newswire at 2018-01-04 08:00:00:000

ROCKFORD, Ill. , Jan. 4, 2018 /PRNewswire/ -- UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR ACQUIRED SHARES OF AKORN INC.'S(NASDAQ:AKRX)COMMON STOCK BETWEEN MAY 6… read more...

FDA advancing plan to streamline generic drug reviews

via: SeekingAlpha at 2018-01-03 12:54:23:000

The FDA released two documents today aimed at making the generic drug application and review process more efficient, the aim of its Drug Competition Action Plan. More news on: Amphastar, ANI Pharmaceuticals, Inc., Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Pomerantz LLP and Glancy Prongay & Murray LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Akorn, Inc. - AKRX

via: Business Wire at 2017-12-28 17:40:00:000

Pomerantz LLP and Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of Illinois, Eastern Division, has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Akorn, Inc…. read more...

FDA issues guidance on development of generic abuse-deterrent opioids

via: SeekingAlpha at 2017-11-21 14:00:19:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. says the agency is taking steps to help drug makers develop approvable generic opioid medications that incorporate abuse-deterrent characteristics. More news on: Teva Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX